Analysts Set Bicycle Therapeutics Limited (NASDAQ:BCYC) Price Target at $21.30

berry sinaga

Shares of Bicycle Therapeutics Limited (NASDAQ:BCYC) have earned a consensus rating of “Buy” from the eight research firms that are presently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 […]

Shares of Bicycle Therapeutics Limited (NASDAQ:BCYC) have earned a consensus rating of “Buy” from the eight research firms that are presently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $21.30.

Several analysts recently weighed in on the stock. Oppenheimer reiterated a “buy” rating and issued a $27.00 price target on shares of Bicycle Therapeutics in a report on Tuesday, July 21st. Canaccord Genuity restated a “buy” rating and set a $23.50 target price on shares of Bicycle Therapeutics in a report on Tuesday, May 12th. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of Bicycle Therapeutics in a report on Thursday, August 6th. Zacks Investment Research upgraded shares of Bicycle Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 6th. Finally, BidaskClub cut shares of Bicycle Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 5th.

NASDAQ:BCYC opened at $18.30 on Friday. The firm’s fifty day simple moving average is $16.70 and its 200 day simple moving average is $14.96. Bicycle Therapeutics has a twelve month low of $6.24 and a twelve month high of $20.10.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.19). The company had revenue of $1.57 million during the quarter, compared to the consensus estimate of $2.11 million. Bicycle Therapeutics had a negative net margin of 434.29% and a negative return on equity of 43.74%. As a group, analysts predict that Bicycle Therapeutics will post -2.38 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the company. UBS Group AG purchased a new position in shares of Bicycle Therapeutics in the 2nd quarter worth about $36,000. Morgan Stanley raised its position in shares of Bicycle Therapeutics by 32,450.0% in the 1st quarter. Morgan Stanley now owns 3,255 shares of the company’s stock worth $44,000 after purchasing an additional 3,245 shares during the last quarter. Squarepoint Ops LLC purchased a new position in shares of Bicycle Therapeutics in the 1st quarter worth about $179,000. Advisor Group Holdings Inc. raised its position in shares of Bicycle Therapeutics by 34,000.0% in the 2nd quarter. Advisor Group Holdings Inc. now owns 34,100 shares of the company’s stock worth $537,000 after purchasing an additional 34,000 shares during the last quarter. Finally, FMR LLC purchased a new position in shares of Bicycle Therapeutics in the 2nd quarter worth about $3,277,000. 33.79% of the stock is owned by hedge funds and other institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.

Further Reading: Cash Asset Ratio

Analyst Recommendations for Bicycle Therapeutics (NASDAQ:BCYC)

Receive News & Ratings for Bicycle Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bicycle Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Source Article

Next Post

What is the 'Delhi Electric Vehicle Policy' launched by CM Arvind Kejriwal?

On August 7, 2020, Chief Minister Arvind Kejriwal launched ‘Delhi Electric Vehicle Policy’ to waive the registration fee and road tax, and to provide an incentive of up to Rs 1.5 lakh for new cars in the national capital. The policy has also been introduced to decrease pollution levels in […]

Subscribe US Now